KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) R&D In Process (2020 - 2025)

Pfizer (PFE) has disclosed R&D In Process for 8 consecutive years, with $212.0 million as the latest value for Q4 2025.

  • On a quarterly basis, R&D In Process rose 140.91% to $212.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 billion, a 1407.48% increase, with the full-year FY2025 number at $1.6 billion, up 1393.52% from a year prior.
  • R&D In Process was $212.0 million for Q4 2025 at Pfizer, down from $1.4 billion in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $1.4 billion in Q3 2025 to a low of $1.0 million in Q3 2022.
  • A 5-year average of $240.8 million and a median of $68.0 million in 2023 define the central range for R&D In Process.
  • Peak YoY movement for R&D In Process: tumbled 99.54% in 2022, then surged 10592.31% in 2025.
  • Pfizer's R&D In Process stood at $706.0 million in 2021, then grew by 24.65% to $880.0 million in 2022, then tumbled by 91.82% to $72.0 million in 2023, then rose by 22.22% to $88.0 million in 2024, then skyrocketed by 140.91% to $212.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's R&D In Process are $212.0 million (Q4 2025), $1.4 billion (Q3 2025), and $2.0 million (Q2 2025).